(A) MyD88 and p-NF-κB protein expression (B) IL-1β, (C) IL-6, and (D) IL-10 production in WT and CD39−/− LPS-primed BMDM stimulated with ATP (500 μM) or BzATP (100 μM). For P2X7 receptor inhibition, samples were pretreated with the P2X7 receptor antagonists oATP (300 μM, for 2 h) or A740003 (0.1 μM, for 30 min) or with imipramine (IMI, 30 μM for 30 min) before priming. Data are expressed as mean ± SEM of three independent experiments analyzed by one-way ANOVA, Turkey tests. Asterisks represent statistically significant differences (p <0.05; *) when comparing WT to CD39−/− or groups. Number signs (#) represent statistically significant differences (p <0.05) when the group pretreated with antagonists were compared to the same stimulated group non-pretreated.